[1]郭俊林,张 立.MMP-2在ST段抬高性心肌梗死中的预后评估价值分析[J].医学信息,2018,(17):71-74.[doi:10.3969/j.issn.1006-1959.2018.17.021]
 GUO Jun-lin,ZHANG Li.Prognostic Value of MMP-2 in ST-segment Elevation Myocardial Infarction[J].Medical Information,2018,(17):71-74.[doi:10.3969/j.issn.1006-1959.2018.17.021]
点击复制

MMP-2在ST段抬高性心肌梗死中的预后评估价值分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年17期
页码:
71-74
栏目:
论著
出版日期:
2018-09-01

文章信息/Info

Title:
Prognostic Value of MMP-2 in ST-segment Elevation Myocardial Infarction
文章编号:
1006-1959(2018)17-0071-04
作者:
郭俊林1张 立2
1.四川省广安市人民医院/四川大学华西广安医院心内科,四川 广安 638000; 2.四川大学华西医院心内科,四川 成都 610041
Author(s):
GUO Jun-lin1ZHANG Li2
1.Guang'an People's Hospital,/Department of Cardiology,West China Guang'an Hospital,Sichuan University,Guang'an 638000,Sichuan,China; 2.Department of Cardiology,West China Hospital,Sichuan University,Chengdu 610041,Sichuan,China
关键词:
ST段抬高性心肌梗死基质金属蛋白酶-2危险性评估
Keywords:
Key words:ST-segment elevation myocardial infarctionMatrix metalloproteinase-2Risk assessment
分类号:
R542.22
DOI:
10.3969/j.issn.1006-1959.2018.17.021
文献标志码:
A
摘要:
目的 通过研究血浆MMP-2在ST段抬高性心肌梗死患者的表达,进一步分析MMP-2对近期的主要不良心血管事件的评估价值。方法 选取我院2013年9月~2015年9月ST段抬高性心肌梗死患者110例作为实验组,选取同期身体健康的体检志愿者50例作为对照组。用酶联免疫吸附试验检测两组患者血浆MMP-2浓度,比较两组男性比例、年龄、BMI、空腹血糖、总胆固醇、血肌酐以及MMP-2水平;通过GFRACE评分核定实验组入院GRACE积分,观察住院期间的MACE发生情况。结果 实验组的男性比例、年龄、空腹血糖、血肌酐以及MMP-2水平均高于对照组,差异具有统计学意义(P<0.05);两组BMI和总胆固醇水平相比,差异无统计学意义(P>0.05)。实验组患者住院期间累计发生MACE共16例(14.55%);基线入院GRACE评分、血浆MMP-2水平预测STEMI患者发生MACE的AUC分别为0.747(SE=0.069,P=0.006,95%CI 0.597~0.863)、0.721(SE=0.077,P=0.016,95%CI 0.567~0.846)。结论 MMP-2参与了急性心肌梗死的发生过程,对STEMI患者在院期间MACE事件的发生有一定的评估价值。
Abstract:
Abstract:Objective To investigate the value of MMP-2 in the evaluation of recent major adverse cardiovascular events by studying the expression of plasma MMP-2 in patients with ST-segment elevation myocardial infarction.Methods A total of 110 patients with ST-segment elevation myocardial infarction from September 2013 to September 2015 were selected as the experimental group.50 healthy volunteers were selected as the control group.The levels of plasma MMP-2 in the two groups were measured by enzyme-linked immunosorbent assay (ELISA).The proportion,age,BMI,fasting blood glucose,total cholesterol,serum creatinine and MMP-2 levels of the two groups were compared.The GRACE scores of the experimental group were confirmed by GFRACE score.Observe the occurrence of MACE during hospitalization.Results The male proportion,age,fasting blood glucose,serum creatinine and MMP-2 levels in the experimental group were higher than those in the control group,the difference was statistically significant(P<0.05).There was no significant difference between the two groups in BMI and total cholesterol levels(P>0.05).A total of 16 patients(14.55%)had a cumulative MACE during the hospitalization period.Baseline admission GRACE score and plasma MMP-2 level predicted AUC of MACE in STEMI patients were 0.747(SE=0.069,P=0.006,95%CI 0.597~0.863),0.721(SE=0.077,P=0.016,95% CI 0.567~0.846). Conclusion MMP-2 is involved in the pathogenesis of acute myocardial infarction,and it has certain evaluation value for the occurrence of MACE events in patients with STEMI.

参考文献/References:

[1]Tanana OS,Sukmanova IA,Ponomarenko IV.The clinical significance of copeptin and matrix metalloproteinases in men with acute coronary syndrome[J].Kardiologiia,2017,57(S3):32-39. [2]Hsu TW,Kuo KL,Hung SC,et al.Progression of kidney disease in non-diabetic patients with coronary artery disease:predictive role of circulating matrix metalloproteinase-2,-3,and-9[J].PLoS One,2013,8(7):e70132. [3]Luedike P,Alatzides G,Papathanasiou M,et al.Circulating macrophage migration inhibitory factor(MIF)in patients with heart failure[J].Cytokine,2018(110):104-109. [4]McAllister DA,Halbesma N,Carruthers K,et al.GRACE score predicts heart failure admission following acute coronary syndrome[J].Eur Heart J Acute Cardiovasc Care,2015,4(2):165-171. [5]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,43(5):380-393. [6]Jakimov T,Mrdovic I,Filipovic B,et al.Comparison of RISK-PCI,GRACE,TIMI risk scores for prediction of major adverse cardiac events in patients with acute coronary syndrome[J].Croat Med J,2017,58(6):406-415. [7]Lin A,Devlin G,Lee M,et al.Performance of the GRACE scores in a New Zealand acute coronary syndrome cohort[J].Heart,2014,100(24):1960-1966. [8]Zhu JJ,Zhao Q,Qu HJ,et al.Usefulness of plasma matrix metalloproteinase-9 levels in prediction of in-hospital mortality in patients who received emergent percutaneous coronary artery intervention following myocardial infarction[J].Oncotarget,2017,8(62):105809-105818. [9]Bamberg F,Truong QA,Koenig W,et al.Differential associations between blood biomarkers of inflammation,oxidation,and lipid metabolism with varying forms of coronary atherosclerotic plaque as quantified by coronary CT angiography[J].Int J Cardiovasc Imaging,2012,28(1):183-192. [10]Mishra A,Srivastava A,Mittal T,et al.Genetic predisposition to left ventricular dysfunction:a multigenic and multi-analytical approach[J].Gene,2014,546(2):309-317. [11]Banday MZ,Sameer AS,Mir AH,et al.Matrix metalloproteinase(MMP) -2,-7 and -9 promoter polymorphisms in colorectal cancer in ethnic Kashmiri population -A case-control study and a mini review[J].Gene,2016,589(1):81-89. [12]Khandelwal G,Jain A,Rathore M.Prediction of Angiographic Extent of Coronary Artery Disease on the Basis of Clinical Risk Scores in Patients of Unstable Angina[J].J Clin Diagn Res,2015,9(11):13-16. [13]Liu R,Lyu SZ,Zhao GQ,et al.Comparison of the performance of the CRUSADE, ACUITY-HORIZONS,and ACTION bleeding scores in ACS patients undergoing PCI:insights from a cohort of 4939 patients in China[J].J Geriatr Cardiol,2017,14(2):93-99. [14]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(1):67-69.

相似文献/References:

[1]郭俊林,张 立.基质金属蛋白酶-2与冠状动脉粥样硬化性疾病的研究进展[J].医学信息,2018,(04):27.[doi:10.3969/j.issn.1006-1959.2018.04.010]
 GUO Jun-lin,ZHANG Li.Progress of the Researchon Matrix Metalloproteinase-2 and Coronary Atherosclerotic Disease[J].Medical Information,2018,(17):27.[doi:10.3969/j.issn.1006-1959.2018.04.010]

更新日期/Last Update: 2018-09-01